

Vms1p is a release factor for the Ribosome-associated Quality control Complex

Olga Zurita Rendón^{1,2*}, Eric K. Fredrickson^{2*}, Conor J. Howard^{3,6*}, Jonathan Van Vranken², Sarah Fogarty^{1,2}, Neal D. Tolley⁴, Raghav Kalia^{2,3,6}, Beatriz A. Osuna^{3,5}, Peter S. Shen², Christopher P. Hill², Adam Frost^{2,3,6,7}, Jared Rutter^{1,2}

¹ Howard Hughes Medical Institute,

² Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112, USA

³ Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158 USA

⁴ Molecular Medicine Program, University of Utah, Salt Lake City, UT, 84112, USA

⁵ Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158 USA

⁶ California Institute for Quantitative Biomedical Research, San Francisco, CA 94158 USA

⁷ Chan Zuckerberg Biohub, San Francisco, CA 94158 USA

*These authors contributed equally to this work

Correspondence: adam.frost@ucsf.edu and rutter@biochem.utah.edu

1 **Eukaryotic cells employ the Ribosome-associated Quality control Complex (RQC) to**
2 **maintain homeostasis despite defects that cause ribosomes to stall. The RQC**
3 **comprises the E3 ubiquitin ligase Ltn1p, the ATPase Cdc48p, and the novel proteins**
4 **Rqc1p and Rqc2p¹⁻³. Following recognition and subunit splitting of stalled ribosomes,**
5 **the RQC detects and assembles on 60S subunits that hold incomplete polypeptides**
6 **linked to a tRNA (60S:peptidyl-tRNA)⁴⁻⁸. Ltn1p cooperates with Rqc1p to facilitate**
7 **ubiquitination of the incomplete nascent chain, marking it for degradation^{7,9,10}. Rqc2p**
8 **stabilizes Ltn1p on the 60S^{3-5,8} and recruits charged tRNAs to the 60S to catalyze**
9 **elongation of the nascent protein with Carboxy-terminal Alanine and Threonine**
10 **extensions, or CAT tails, via a mechanism that is distinct from canonical translation^{4,10}.**
11 **CAT-tailing mobilizes and exposes lysine residues in the nascent chain, especially**
12 **those stalled within the exit tunnel, thereby supporting efficient ubiquitination^{10,11}. If**
13 **the ubiquitin-proteasome system is overwhelmed or unavailable, CAT-tailed nascent**
14 **chains aggregate in the cytosol or within organelles like the mitochondria¹²⁻¹⁴. Here we**
15 **identify Vms1p as the tRNA hydrolase that releases nascent polypeptides for**
16 **extraction and degradation in the RQC pathway.**

17 Like other RQC components, Vms1p is conserved throughout Eukarya and promotes protein
18 quality control in diverse settings. In *S. cerevisiae*, Vms1p localizes to mitochondria in
19 response to mitochondrial stress or damage^{15,16}. Mutants lacking Vms1p are sensitive to
20 rapamycin, which impairs ribosomal protein synthesis^{17,18}, although the mechanism for this
21 sensitivity is unknown. We found that the *vms1Δ* strain is also sensitive to the protein
22 synthesis inhibitor cycloheximide (CHX), as are other RQC mutants in a sensitizing *SKI*
23 mutant background¹¹. Surprisingly, deletion of any one of the RQC system components
24 *RQC1*, *RQC2* or *LTN1*, was sufficient to reverse the lethality of the *vms1Δ* mutant in CHX

25 **(Fig. 1a)**. By contrast, deletion of the no-go decay^{19,20} components *DOM34* or *SKI7* had no
26 effect. These data suggest that CHX causes accumulation of an RQC product that is toxic
27 unless Vms1p is available to detoxify it.

28 The RQC assembles on a failed 60S subunit to both ubiquitinate and elongate nascent
29 polypeptides with CAT tails. To determine whether one or both of these activities generate
30 the putative toxic RQC product, we eliminated them separately by expressing a CAT-tailing-
31 defective Rqc2p mutant (*RQC2^{D98Y}*)^{4,8,14} or a variant of Ltn1p deficient in ubiquitination
32 (*LTN1^{W1542E}*)^{10,21}. CAT-tailing by Rqc2p was dispensable, but ubiquitination by Ltn1p was
33 essential, for conferring CHX sensitivity on a *vms1Δ* mutant strain **(Fig. 1b)**. Similar to *RQC2*
34 and *LTN1* **(Fig. 1b)**, plasmid expression of wild type *RQC1* was sufficient to reverse the
35 rescue of *vms1Δ* cycloheximide sensitivity conferred by *RQC1* deletion **(Extended Data Fig.**
36 **1a)**.

37 In light of the association between Vms1 activity and mitochondrial stress, we examined the
38 ability of these single and double mutant strains to grow in glycerol medium, which requires
39 mitochondrial respiration. Interestingly, deletion of *LTN1*—but not *RQC1*, *RQC2* or *DOM34*—
40 strongly impaired glycerol growth of *vms1Δ* cells **(Extended Data Fig. 1b)**. Similarly, *ski7Δ*
41 *vms1Δ* double mutant cells also exhibited partially impaired glycerol growth **(Extended Data**
42 **Fig. 1b)**. These data indicate a specific relationship between Vms1p, RQC function, and
43 mitochondrial homeostasis, which is consistent with a recent report that stalled polypeptides
44 that cannot be ubiquitinated by Ltn1p accumulate within mitochondria²².

45 These genetic interactions prompted us to determine whether Vms1p physically interacts with
46 members of the RQC, as has been reported previously^{1,3,22}. As expected, isolation of Rqc2p-
47 HA co-immunoprecipitated Vms1p-V5 whereas Rqc1p-HA or Ltn1p-HA showed minimal
48 Vms1p interaction **(Fig. 1c and Extended Data Fig. 1c-d)**. Consistently, both Rqc2p and

49 Vms1p co-migrated with the 60S ribosome subunit during sucrose gradient sedimentation
50 following CHX treatment (**Fig. 1d, Extended Data Fig. 1e**). Co-migration of Vms1p with the
51 60S ribosome was not affected by either deletion of *RQC2* or by expression of WT or a CAT-
52 tailing defective, D98Y, mutant of Rqc2p (**Extended Data Fig. 1e**). Similarly, neither deletion
53 nor overexpression of Vms1p from the strong *GAL1* promoter in galactose medium had any
54 effect on the co-migration of Rqc2p with the 60S ribosomal subunit (**Extended Data Fig.**
55 **1e,f**).

56 These genetic and physical interactions motivated us to evaluate whether RQC substrates
57 accumulate in *VMS1* mutant cells. We utilized a well-characterized mRNA that encodes
58 FLAG-tagged GFP followed by a hammerhead ribozyme that self-cleaves in vivo (FLAG-
59 GFP^{Rz}, **Fig. 2a**)^{4,23} to generate a truncated mRNA encoding FLAG-GFP without a stop codon
60 or poly-A tail. Translation of this mRNA triggers ribosome stalling and targeting to the RQC
61 system. Deletion of *SKI7* enhances expression of GFP by inhibiting degradation of the
62 cleaved mRNA²⁴. We confirmed that deletion of *RQC1*, *RQC2*, and *LTN1* each lead to
63 accumulation of FLAG-GFP^{Rz}, whereas the nascent chain failed to accumulate in the *ski7Δ*
64 single mutant (**Fig. 2a-c, Extended Data Fig. 2a**). Loss of Vms1p also led to accumulation of
65 FLAG-GFP^{Rz} to a level similar to that observed for the core RQC components (**Fig. 2a-c,**
66 **Extended Data Fig. 2b**). Combination of *VMS1* deletion with the deletion of *RQC1*, *RQC2*
67 and *LTN1* had no additive effect on GFP accumulation (**Fig. 2b**). Immunoblot analysis
68 showed similar results for the single, double and triple mutant strains, in which RQC2-
69 dependent, high molecular weight aggregates are also apparent (**Fig. 2c, Extended Data**
70 **Fig. 2b**)¹²⁻¹⁴. Loss of *DOM34* led to decreased accumulation of GFP fluorescence, even in
71 the *vms1Δ* strain, consistent with Dom34p's upstream role in ribosome splitting and
72 suggestive of alternative pathways for degrading nascent chains when the Dom34p/Hbs1p

73 subunit splitting activity is unavailable (**Fig. 2a-c**). Interestingly, accumulation of FLAG-GFP^{Rz}
74 in *vms1Δ* mutant cells occurs despite lower mRNA abundance (**Extended Data Fig. 2c**).

75 In addition to the FLAG-GFP^{Rz} construct, which generates a cytosolic RQC substrate, we
76 also examined RQC activity on fumarase, which is encoded by the *FUM1* gene and co-
77 translationally imported into the mitochondria²⁵. As with FLAG-GFP^{Rz}, fluorescence from the
78 Fum1-FLAG-GFP^{Rz} construct, expressed from the native *FUM1* promoter, was also
79 maintained at a low level in the *ski7Δ* mutant strain (**Fig. 2d**). Deletion of *VMS1*, *RQC1*,
80 *RQC2*, or *LTN1* each led to profound accumulation of GFP fluorescence, almost all of which
81 colocalized with mitochondria-targeted RFP (mtRFP). The *vms1Δ*, *rqc1Δ* and *ltn1Δ* mutants,
82 which retain Rqc2p and CAT-tailing activity, all exhibited Fum1-GFP aggregates within or
83 near mitochondria, comparable to recent observations of other mitochondria-destined
84 nascent chains²² (**Fig. 2d**). The *rqc2Δ* mutant exhibited a more uniformly mitochondrial
85 localization pattern (**Fig. 2d**), consistent with the model that CAT-tailing mediates intra-
86 mitochondrial aggregation of polypeptides that stall during co-translational import²². Together,
87 these data demonstrate that Vms1p is required for the degradation of substrates derived from
88 truncated mRNAs, whether they are destined for an organelle or the cytosol.

89 Understanding of how Vms1p facilitates the clearance of stalled translation products was
90 guided by our recent crystal structure determination of *S. cerevisiae* Vms1p (**Fig. 3a-b**)²⁶.

91 This structure includes the highly conserved central region of Vms1p, which we named the
92 Mitochondrial Targeting Domain (MTD) because it is necessary and sufficient for
93 mitochondrial localization in response to stress¹⁵. This localization activity requires a
94 hydrophobic groove along the bottom of the MTD and direct binding to ergosterol peroxide²⁶.

95 Intriguingly, the Vms1p MTD structure resembles structures of the catalytic domain of
96 eukaryotic peptide chain release factor subunit 1 (eRF1), as well as Dom34p and RNaseE,

97 which both resemble tRNA hydrolases²⁷⁻³⁰ (**Fig. 3b**, **Extended Data Fig. 3a**). The only region
98 of the Vms1p MTD that diverges substantially from the release factor fold is the face of the
99 MTD that mediates mitochondrial localization²⁶ (**Fig. 3b**). The loop of eRF1 that harbors the
100 signature GGQ motif—which catalyzes the hydrolytic attack on the peptidyl-tRNA ester
101 bond—and the orthologous loop of the Vms1p MTD, can both be unstructured when not
102 bound to the ribosome^{28,30} (**Fig. 3b**).

103 Sequence alignment showed that although Vms1p lacks a strict GGQ motif characteristic of
104 eRF1p, it does possess an invariant glutamine that aligns with the catalytic glutamine of
105 eRF1 (**Fig. 3c**). In yeast Vms1p, that glutamine residue is embedded within a GGSQ motif
106 that is reminiscent of the eRF1 catalytic GGQ, while in other species the conservation other
107 than the initial glycine and glutamine is less apparent (**Fig. 3c-d**). The Vms1p MTD lacks
108 similarity to the non-catalytic eRF1 domain 1, which discriminates stop codons from sense
109 codons³⁰. This is consistent with Vms1p functioning in stop codon-independent tRNA
110 hydrolysis within a 60S, rather than 80S, ribosome.

111 These observations inspired us to determine whether Vms1p enables the extraction of failed
112 translation products from the stalled 60S by hydrolyzing the ester bond anchoring them to
113 tRNA. We first asked which residues and regions are required for the genetic functions of
114 *VMS1*. We first tested an Hb ϕ T motif just N-terminal to the conserved 'GxxQ' motif that
115 mediates ribosome interactions of eRF1 (**Fig. 3c-d**). Vms1p mutants of these residues,
116 H279A, H283A, R284A and T286A, were indistinguishable from WT, while the Y285A mutant
117 exhibited a partial CHX sensitivity (**Fig. 3f**). In contrast, mutation of the 'GxxQ' residues G292
118 and Q295 and the highly conserved R288 residue conferred strong loss-of-function
119 phenotypes (**Fig. 3e**). Deletion of S294 to convert the GGSQ of *S. cerevisiae* Vms1p into a
120 GGQ motif, as in eRF1, abrogated *VMS1* function (**Figure 3e**). While all of these 'GxxQ'

121 'mutants failed to confer resistance to 200 ng/ml CHX, only the R288A and G292A/G293A
122 mutants were inactive at the lowest (100 ng/ml) concentration of CHX tested (**Figure 3e**).
123 Interestingly, both of these mutants also failed to rescue glycerol growth in an *ltn1Δ vms1Δ*
124 double mutant, whereas wild-type *VMS1* and the other mutants did rescue growth (**Extended**
125 **Data Fig. 3b**). The R288A, GG292/3AA and Q295L mutants also exhibited enhanced
126 accumulation of FLAG-GFP^{Rz} in the *ski7Δ* background similar to the *vms1Δ* mutant
127 (**Extended Data Fig. 3d**). Importantly, the Vms1p mutants interact normally, if not more
128 strongly, with Rqc2p based on co-immunoprecipitation experiments (**Extended Data Fig. 3e**).
129 In light of these observations, we hereafter refer to the MTD as the MTD/eRFL domain,
130 where eRFL refers to eRF1-like.

131 In addition to these loop residues, the ability of Vms1p to confer complete CHX resistance in
132 both *vms1Δ* and *ski7Δ vms1Δ* also required the VCP-interacting motif (VIM), which mediates
133 interaction with Cdc48p/VCP/p97¹⁶ (**Extended Data Fig. 3c**). Interestingly, the VIM is not
134 required for growth of the *ltn1Δ vms1Δ* double mutant on glycerol (**Extended Data Fig. 3c**),
135 which indicates that mitochondrial homeostasis can be maintained even without Cdc48p
136 binding.

137 To directly test whether Vms1p catalyzes peptidyl-tRNA hydrolysis, we utilized our recently
138 described *S. cerevisiae* in vitro translation (SciVT) system to monitor the synthesis and fate
139 of a robust stalling reporter and its peptidyl-tRNA intermediate¹⁰. RQC-intact extracts
140 translate this reporter, split the stalled 80S ribosome into constituent 60S and 40S subunits,
141 elongate the nascent chain with a CAT tail, and ubiquitinate exposed Lys residues. These
142 extracts also hydrolyze the peptidyl-tRNA ester bond to generate the released polypeptide
143 (**Fig. 4a**)¹⁰. We observed that extracts prepared from *vms1Δ* mutant cells also produced

144 peptidyl-tRNA conjugates, but loss of the peptidyl-tRNA species and appearance of the
145 released translation product were slower than in WT extracts (**Fig. 4a-b**). This is somewhat
146 obscured by the fact that the *vms1* Δ mutant has lower overall translation, which leads to a
147 decreased amount of the free nascent chain and peptidyl-tRNA conjugates. We performed a
148 similar experiment in the *ski7* Δ and *ski7* Δ *vms1* Δ mutant strains and found that in the *ski7* Δ
149 background the deletion of *VMS1* conferred a much more obvious stabilization of the
150 peptidyl-tRNA species and qualitatively delayed release of the polypeptides (**Fig. 4c-d**). In
151 this *ski7* Δ background, deletion of *RQC2* conferred a modest stabilization of the peptidyl-
152 tRNA conjugate¹⁰ and deleting *RQC2* had little effect on the *ski7* Δ *vms1* Δ double mutant
153 (**Extended Data Fig. 4a**). We next purified full-length and C-terminally truncated (1-417) *S.*
154 *cerevisiae* Vms1p and found that each of these proteins dramatically accelerated the
155 production of the released polypeptide in a dose-dependent manner in WT, *rqc2* Δ and *vms1* Δ
156 extracts (**Fig. 4e, Extended Data Fig. 4b**). Importantly, the 1-417 truncation mutant lacks the
157 C-terminal VIM domain and is unable to interact with Cdc48p (**Extended data Fig. 3e**). We
158 therefore conclude that while the Vms1-Cdc48 interaction is important for CHX resistance
159 and other RQC-related functions, it is dispensable for peptidyl-tRNA hydrolysis.

160 We next tested release factor activity of the MTD/eRFL domain structure-based mutants
161 described above. R288A and G292A/G293A mutants had no hydrolysis activity, even at 10-
162 fold higher concentration than the concentration at which WT Vms1p catalyzed complete
163 tRNA release (**Fig. 4f**). The Q295L, G292A, and Δ S294 mutants also exhibited strongly
164 impaired release factor activity (**Fig. 4f and Extended Data Fig. 4c**).

165 Our data have identified a key constituent of the RQC pathway in Eukarya: a tRNA hydrolase
166 that liberates failed polypeptides from the aberrant 60S:peptidyl-tRNA species that
167 accumulate when ribosomes stall and split apart. Without this activity, translation products

168 remain anchored in 60S ribosomes, which therefore cannot be recycled for future use. The
169 dual functions of the Vms1p MTD/eRFL identified here as an RQC pathway release factor
170 and earlier as a targeting domain in mitochondrial stress responses, portend exciting future
171 work at the intersection of proteostasis and organelle homeostasis. We have previously
172 reported that Vms1p localizes to mitochondria under conditions of mitochondrial damage or
173 cellular stressors, including rapamycin treatment, by binding to the oxidized sterol ergosterol
174 peroxide^{15,16,26}. The MTD/eRFL domain is necessary and sufficient for this localization, which
175 is mediated by a direct interaction between a face of the MTD/eRFL domain that should
176 remain exposed even when the domain is in the 'A-site' of the 60S and the catalytic GGSQ
177 loop is presumably reaching into the peptidyl transferase center to catalyze hydrolysis of the
178 peptidyl-tRNA ester bond. While the relationship between mitochondrial localization and
179 RQC-coupled release factor activity remains unclear, it is intriguing to speculate that this is
180 indicative of a role for Vms1p—and the RQC as a whole—in the response to mitochondrial
181 stress. Consistent with this possibility, *ltn1Δ vms1Δ* and *ski7Δ vms1Δ* double mutant cells
182 exhibit impaired glycerol growth, which correlates with impaired mitochondrial respiration²².
183 We therefore propose that Vms1p is required for the resolution of peptidyl-tRNA conjugates
184 of stalled nascent chains in the cytosol as well as those destined for organelles like the
185 mitochondria, where it might mediate a particular role in protecting mitochondria from
186 proteostasis challenges.

187

188 **Methods**

189 **Yeast strains and growth conditions**

190 *Saccharomyces cerevisiae* BY4741 (*MATa*, *his3 leu2 met15 ura3*) was used as the
191 wild-type strain. Each mutant was generated in diploid cells using a standard PCR-based

192 homologous recombination method. The genotypes of all strains used in this study are listed
193 in **Extended Data Table 1A**. Yeast transformations were performed by the standard TE/LiAc
194 method and transformed cells were recovered and grown in synthetic complete glucose (SD)
195 medium lacking the appropriate amino acid(s) for selection. The medium used included YPA
196 and synthetic minimal medium supplemented with 2% glucose or 3% glycerol. Cycloheximide
197 was added at a final concentration of 100 ng/ml or 200 ng/ml when indicated.

198 All plasmid constructs were generated by PCR and cloned into the yeast expression
199 vectors pRS413, pRS14 or pRS416 as indicated in **Extended Data Table 1B**.

200 Growth assays were performed using synthetic minimal media supplemented with the
201 appropriate amino acids and indicated carbon source. For plate-based growth assays,
202 overnight cultures were back-diluted to equivalent ODs and spotted as 10-fold serial dilutions.
203 Cells were grown at 30°C.

204

205 Immunoprecipitations

206 p^{VMS1} -VMS1-V5 (or VMS1 mutant) was co-expressed with an endogenous promoter-
207 HIS6-HA2 tagged RQC component (RQC1, RQC2, LTN1) in the cognate double mutant
208 strain. ~50 OD were harvested in log phase and resuspended in IP buffer (20 mM Tris pH
209 7.4, 50 mM NaCl, 0.2% TritonX-100), vortexed 10 X 1min, clarified via centrifugation, and
210 added to anti-HA magnetic beads (Thermo scientific #88836). After 4 hours of incubation,
211 beads were pelleted via magnet and washed 4X with 1 ml of IP buffer. Proteins were eluted
212 with 50 μ l of 2X Laemmli buffer (20% glycerol, 125 mM Tris-HCl pH 6.8, 4% SDS, 0.02%
213 bromophenol blue).

214

215 Polysome profiling

216 Yeast cultures were grown to $OD_{600} \sim 1$, cycloheximide was added to a final
217 concentration of 0.05mg/ml, and cells were harvested by centrifugation five minutes later.
218 Cell pellets were washed in buffer A (20 mM Tris-HCl pH 7.4, 50 mM KCl, 10 mM $MgCl_2$, 1
219 mM DTT, 100 μ g/mL cycloheximide, 1X RNasecure [Ambion], and 1X yeast protease
220 inhibitor [Sigma]). Pellets were weighted and resuspended in 1.3 volumes of Buffer A. An
221 equal volume of glass beads was added and suspensions were vortexed for 30 secs a total
222 of 8 times interspersed with 1 min. incubation on ice. Following centrifugation at 3,000 x g for
223 5 min, supernatant was centrifuged at 11,300 x g for 2 min at 4°C, after which supernatant
224 was centrifuged at 11,300 x g for 10 min. Protein extracts were overlaid onto a linear sucrose
225 gradient of 15-50% and centrifuged at 234,600 x g for 90 min. The gradients were passed
226 through a continuous-flow chamber and monitored at 254 nm with a UV absorbance detector
227 (ISCO UA-6) to obtain ribosomal profiles. Fractions (16) were collected, resuspended in 2X
228 Laemmli sample buffer supplemented with 2.5% beta-mercaptoethanol, and analyzed by
229 western blotting.

230

231 **SDS-PAGE**

232 Whole Cell Extracts were prepared from 3-5 OD of cells at $OD_{600} \sim 1.5$ by solubilization
233 in 250 μ l of 2 M LiAc, incubated for 8 min on ice followed by centrifugation at 0.9 x g for 5
234 minutes at 4°C. The pellet was resuspended in 250 μ l of 0.4 M NaOH and incubated on ice
235 for 8 min. followed by centrifugation at 16,000 x g for 3 min. Next, the pellet was resuspended
236 in 1X Laemmli buffer with 2.5% beta-mercaptoethanol, boiled for 5 minutes, and centrifuged
237 at 0.9 x g for 1 min. Supernatants were collected and loaded onto acrylamide:bisacrylamide
238 (37.5:1) gels. Subsequent immunoblotting was done with the indicated antibodies: HA (PRB-
239 101C-200), V5 (ab9116), FLAG (F7425), Pgk1: (ab113687) and Rpl3 (scRPL3).

240

241 **Fluorescence microscopy**

242 WT (BY4741) or derived mutant strains were transformed with a plasmid expressing
243 mitochondria-targeted (ATPase subunit, Su9) RFP, mtRFP, and plasmids expressing
244 6XFlag3XHis-GFP-Rz or FUM1-6XFlag3XHis-GFP-Rz under the *GPD* or native *FUM1*
245 promoter, respectively. The cells were grown to mid-log phase and imaged using the Axio
246 Observer Z1 imaging system (Carl Zeiss). Digital fluorescence and differential interference
247 contrast (DIC) images were acquired using a monochrome digital camera (AxioCam MRm)
248 and analyzed using the Zen 2 software (Carl Zeiss).

249

250 **Fluorescence assisted cell sorting**

251 GFP-expressing strains and untransformed control were grown to $OD_{600} \sim 1$ and
252 pelleted by centrifugation at 100 x g for 5 min. Cell pellets were washed once in 1X PBS
253 buffer, resuspended in 1 ml of 1X PBS, and analyzed using the BDFACSCanto Analyzer (488
254 laser and optical filter FITC). 30,000 events were measured and the median values of three
255 independent biological replicates were analyzed by unpaired *Student t*-test (two-tailed)
256 confidence interval value set to $p < 0.05$. Error bars represent standard error of the mean. This
257 analysis was done using the statistics software: Graphpad Prism 6.

258

259 **Protein Expression and Purification**

260 For the His₁₂ tagged proteins, constructs were transformed into JRY1734 (*pep4::HIS3*
261 *prb1::LEU2 bar1::HISG lys2::GAL1/10-GAL4*) and grown in synthetic media lacking Uracil
262 with 3% glycerol and 2% ethanol. When the OD_{600} reached ~ 0.5 , 0.5% galactose was added
263 to the cultures, which were grown for another 6 hours before harvesting by centrifugation,
264 washing of the pellet with sterile H₂O, and flash freezing in liquid nitrogen. Cells were lysed
265 using a pulverizer (SPEX SamplePrep 6870), and the lysed powder was thoroughly

266 resuspended in lysis buffer (20 mM Tris pH 8.0, 300 mM NaCl, 5% glycerol) supplemented
267 with protease inhibitors (aprotinin, leupeptin, pepstatin A, and PMSF) (Sigma). The
268 resuspended lysate was clarified by centrifugation and added to Ni-NTA resin (Qiagen
269 #30250) for 1 hour, washed with 10 CV of lysis buffer, 10 CV of lysis buffer with 40 mM
270 imidazole, and eluted with lysis buffer made up with 250 mM imidazole. Eluted protein was
271 dialyzed into IVT-compatible buffer (20 mM HEPES-KOH pH7.4, 150mM KOAc, 5% glycerol,
272 2mM DTT) and concentrated.

273

274 ***Saccharomyces cerevisiae* in vitro translation (SciVT)**

275 Preparation of in vitro translation extracts, mRNA, and in vitro translation reactions
276 was performed as previously described¹⁰. Briefly, *S. cerevisiae* strains were cryo-lysed and
277 cell debris was cleared by sequential centrifugation before dialysis into fresh lysis buffer.
278 mRNAs were generated by run-off transcription from PCR-amplified templates of 3xHA-
279 NanoLuciferase to produce transcripts lacking a stop codon and 3'UTR (truncated quality
280 control substrate). Transcription products were capped and extracted prior to freezing for use
281 in SciVTs. For SciVT reactions, extracts were first treated with MNase to remove
282 endogenous mRNAs and then supplemented with 480 ng mRNA to initiate translation.
283 Reaction aliquots were sampled at indicated time points by quenching in 2X Laemmli Sample
284 Buffer. Proteins were separated by SDS-PAGE, and HA-tagged translation products were
285 visualized by immunoblotting (Roche3F10). To quantify release, the abundance of peptidyl-
286 tRNA was measured with Fiji (<https://imagej.net/Fiji>) and normalized as percentage of the
287 initial 15 min time point. Mean values of at least 2 biological replicates and 2-3 technical
288 replicates were analyzed and plotted in Prism (GraphPad software). *P*-values were calculated
289 using a 2-way ANOVA as follows: WT vs. *vms1Δ*, $F= 28.62$, $DFn= 1$ and $F= 76.42$, $DFn= 3$
290 for genotype and time, respectively, and *ski7Δ* vs. *ski7Δ vms1Δ*, $F= 561.69$, $DFn= 1$ and $F=$

291 357.63, $DFn= 3$ for genotype and time, respectively. Error bars represent standard error of
292 the mean. The ramps of panel (e) represent a decreasing titration series of 4.2 μM , 0.42 μM ,
293 0.21 μM and 0.105 μM final protein concentrations. In Figure 4f and Extended Data Figure
294 4c, 1x and 1/10 refer to final protein concentrations of 4.2 μM and 0.42 μM , respectively.

295

296 **Quantitative RT-PCR**

297 RNA was purified from 40 ml of yeast cultures grown to $OD_{600} \sim 1$. Pelleted cells were
298 washed once with water and resuspended in 700 μl of Trizol reagent (Ambion). An equal
299 volume of glass beads was added and suspensions were vortexed for 30 secs intervened
300 with 1 min. rest intervals. Next, the manufacture's protocol from the Direct-zol kit (Zymo
301 research: R2050-11-330) was followed. cDNA was obtained from 0.5 μg of purified RNA
302 using the High-capacity cDNA Reverse Transcription kit (4368814) from Applied Biosystems.
303 qPCR was performed using the LightCycler 480 SYBR Green I Master (04707516001) from
304 Roche and using a FLAG-HIS and Actin primer pairs. qPCR analysis was done by Absolute
305 Quantification/ 2^{nd} derivative of three independent biological replicates, each performed in
306 triplicate. The statistical analysis of mRNA transcript abundance was done after normalization
307 with Actin. The statistics software Graphpad Prism 6 was used to performed a *Student* t-test
308 (unpaired two-tail) with a confidence interval value of $p < 0.05$. Error bars represent standard
309 error of the mean.

310

311 **References**

312 1 Brandman, O. *et al.* A ribosome-bound quality control complex triggers degradation of
313 nascent peptides and signals translation stress. *Cell* **151**, 1042-1054,
314 doi:10.1016/j.cell.2012.10.044 (2012).

- 315 2 Verma, R., Oania, R. S., Kolawa, N. J. & Deshaies, R. J. Cdc48/p97 promotes
316 degradation of aberrant nascent polypeptides bound to the ribosome. *Elife* **2**, e00308,
317 doi:10.7554/eLife.00308 (2013).
- 318 3 Defenouillere, Q. *et al.* Cdc48-associated complex bound to 60S particles is required
319 for the clearance of aberrant translation products. *Proc Natl Acad Sci U S A* **110**,
320 5046-5051, doi:10.1073/pnas.1221724110 (2013).
- 321 4 Shen, P. S. *et al.* Protein synthesis. Rqc2p and 60S ribosomal subunits mediate
322 mRNA-independent elongation of nascent chains. *Science* **347**, 75-78,
323 doi:10.1126/science.1259724 (2015).
- 324 5 Shao, S., Brown, A., Santhanam, B. & Hegde, R. S. Structure and assembly pathway
325 of the ribosome quality control complex. *Mol Cell* **57**, 433-444,
326 doi:10.1016/j.molcel.2014.12.015 (2015).
- 327 6 Shao, S. & Hegde, R. S. Reconstitution of a minimal ribosome-associated
328 ubiquitination pathway with purified factors. *Mol Cell* **55**, 880-890,
329 doi:10.1016/j.molcel.2014.07.006 (2014).
- 330 7 Shao, S., von der Malsburg, K. & Hegde, R. S. Listerin-dependent nascent protein
331 ubiquitination relies on ribosome subunit dissociation. *Mol Cell* **50**, 637-648,
332 doi:10.1016/j.molcel.2013.04.015 (2013).
- 333 8 Lyumkis, D. *et al.* Structural basis for translational surveillance by the large ribosomal
334 subunit-associated protein quality control complex. *Proc Natl Acad Sci U S A* **111**,
335 15981-15986, doi:10.1073/pnas.1413882111 (2014).
- 336 9 Bengtson, M. H. & Joazeiro, C. A. Role of a ribosome-associated E3 ubiquitin ligase in
337 protein quality control. *Nature* **467**, 470-473, doi:10.1038/nature09371 (2010).

- 338 10 Osuna, B. A., Howard, C. J., Kc, S., Frost, A. & Weinberg, D. E. In vitro analysis of
339 RQC activities provides insights into the mechanism and function of CAT tailing. *Elife*
340 **6**, doi:10.7554/eLife.27949 (2017).
- 341 11 Kostova, K. K. *et al.* CAT-tailing as a fail-safe mechanism for efficient degradation of
342 stalled nascent polypeptides. *Science* **357**, 414-417, doi:10.1126/science.aam7787
343 (2017).
- 344 12 Choe, Y. J. *et al.* Failure of RQC machinery causes protein aggregation and
345 proteotoxic stress. *Nature* **531**, 191-195, doi:10.1038/nature16973 (2016).
- 346 13 Defenouillere, Q. *et al.* Rqc1 and Ltn1 Prevent C-terminal Alanine-Threonine Tail
347 (CAT-tail)-induced Protein Aggregation by Efficient Recruitment of Cdc48 on Stalled
348 60S Subunits. *J Biol Chem* **291**, 12245-12253, doi:10.1074/jbc.M116.722264 (2016).
- 349 14 Yonashiro, R. *et al.* The Rqc2/Tae2 subunit of the ribosome-associated quality control
350 (RQC) complex marks ribosome-stalled nascent polypeptide chains for aggregation.
351 *Elife* **5**, e11794, doi:10.7554/eLife.11794 (2016).
- 352 15 Heo, J. M., Nielson, J. R., Dephoure, N., Gygi, S. P. & Rutter, J. Intramolecular
353 interactions control Vms1 translocation to damaged mitochondria. *Mol Biol Cell* **24**,
354 1263-1273, doi:10.1091/mbc.E13-02-0072 (2013).
- 355 16 Heo, J. M. *et al.* A stress-responsive system for mitochondrial protein degradation. *Mol*
356 *Cell* **40**, 465-480, doi:10.1016/j.molcel.2010.10.021 (2010).
- 357 17 Jefferies, H. B., Reinhard, C., Kozma, S. C. & Thomas, G. Rapamycin selectively
358 represses translation of the "polypyrimidine tract" mRNA family. *Proc Natl Acad Sci U*
359 *S A* **91**, 4441-4445 (1994).
- 360 18 Jefferies, H. B. *et al.* Rapamycin suppresses 5'TOP mRNA translation through
361 inhibition of p70s6k. *EMBO J* **16**, 3693-3704, doi:10.1093/emboj/16.12.3693 (1997).

- 362 19 Shoemaker, C. J. & Green, R. Translation drives mRNA quality control. *Nat Struct Mol*
363 *Biol* **19**, 594-601, doi:10.1038/nsmb.2301 (2012).
- 364 20 Tsuboi, T. *et al.* Dom34:hbs1 plays a general role in quality-control systems by
365 dissociation of a stalled ribosome at the 3' end of aberrant mRNA. *Mol Cell* **46**, 518-
366 529, doi:10.1016/j.molcel.2012.03.013 (2012).
- 367 21 Yang, J., Hao, X., Cao, X., Liu, B. & Nystrom, T. Spatial sequestration and
368 detoxification of Huntingtin by the ribosome quality control complex. *Elife* **5**,
369 doi:10.7554/eLife.11792 (2016).
- 370 22 Izawa, T. *et al.* Cytosolic Protein Vms1 Links Ribosome Quality Control to
371 Mitochondrial and Cellular Homeostasis. *Cell* **0**, doi:10.1016/j.cell.2017.10.002 (2017).
- 372 23 Kobayashi, K. *et al.* Structural basis for mRNA surveillance by archaeal Pelota and
373 GTP-bound EF1alpha complex. *Proc Natl Acad Sci U S A* **107**, 17575-17579,
374 doi:10.1073/pnas.1009598107 (2010).
- 375 24 Meaux, S. & Van Hoof, A. Yeast transcripts cleaved by an internal ribozyme provide
376 new insight into the role of the cap and poly(A) tail in translation and mRNA decay.
377 *RNA (New York, N.Y.)* **12**, 1323-1337, doi:10.1261/rna.46306 (2006).
- 378 25 Yogev, O., Karniely, S. & Pines, O. Translation-coupled translocation of yeast
379 fumarase into mitochondria in vivo. *J Biol Chem* **282**, 29222-29229,
380 doi:10.1074/jbc.M704201200 (2007).
- 381 26 Nielson, J. R. *et al.* Sterol Oxidation Mediates Stress-Responsive Vms1 Translocation
382 to Mitochondria. *Mol Cell* **68**, 673-685 e676, doi:10.1016/j.molcel.2017.10.022 (2017).
- 383 27 Holm, L. & Rosenstrom, P. Dali server: conservation mapping in 3D. *Nucleic Acids*
384 *Res* **38**, W545-549, doi:10.1093/nar/gkq366 (2010).

- 385 28 Song, H. *et al.* The crystal structure of human eukaryotic release factor eRF1--
386 mechanism of stop codon recognition and peptidyl-tRNA hydrolysis. *Cell* **100**, 311-321
387 (2000).
- 388 29 Graille, M., Chaillet, M. & van Tilbeurgh, H. Structure of yeast Dom34: a protein related
389 to translation termination factor Erf1 and involved in No-Go decay. *J Biol Chem* **283**,
390 7145-7154, doi:10.1074/jbc.M708224200 (2008).
- 391 30 Brown, A., Shao, S., Murray, J., Hegde, R. S. & Ramakrishnan, V. Structural basis for
392 stop codon recognition in eukaryotes. *Nature* **524**, 493-496, doi:10.1038/nature14896
393 (2015).

394

395 **Data availability**

396 The authors declare that the data supporting the findings of this study are available within the
397 paper and its supplementary information files.

398 Further relevant data on the genes studied in this manuscript (*VMS1*: YDR049W, *RQC1*:
399 YDR333C, *RQC2*: YPL009C, *LTN1*: YMR2476, *SKI7*: YOR076C, *DOM34*: YNL01W) can be
400 found at: <https://www.yeastgenome.org>

401

402 **Acknowledgements**

403 This work was supported by a Faculty Scholar grant from the Howard Hughes Medical
404 Institute (A.F.), the Searle Scholars Program (A.F.), NIH grant GM115129 (to C.P.H. and
405 J.R.), a grant from the Nora Eccles Treadwell Foundation (to J.R. and C.P.H.), NIH grant
406 1DP2GM110772-01 (A.F.), training grants T32HL007576, AHA 14POST20380216, and
407 T32DK007115 (E.K.F.), a Hillblom Graduate Research fellowship (C.J.H.), a Heyman
408 Discovery fellowship (B.A.O), and the Howard Hughes Medical Institute (J.R.). A.F. is a Chan
409 Zuckerberg Biohub investigator. This work was supported by the University of Utah Flow

410 Cytometry Facility in addition to the National Cancer Institute through Award
411 Number 5P30CA042014-24.

412

413 **Author contributions**

414 O.Z.R., E.K.F., C.J.H., J.R, and A.F. designed the study and wrote the manuscript. N.D.T.
415 and J.V.V. ran the polysome assays. O.Z.R., E.K.F., C.J.H. collected the data. J.V.V. and
416 S.F. generated plasmid constructs and yeast strains. C.P.H helped determine and analyze
417 the Vms1 structure. R.K. performed structural homology modeling and alignments. B.A.O
418 helped with the IVT assays. P.S. helped with the co-immunoprecipitation experiments. All
419 authors commented and approved of the final manuscript.


420

421 **Author information**

422 Authors declare no competing interests.

423 Correspondence: adam.frost@ucsf.edu and rutter@biochem.utah.edu

Figure 1




424 **Figure 1. Vms1 physically and genetically interacts with the RQC.**

425 (a, b) Serial dilutions of indicated strains were spotted on media containing glucose or
426 glucose supplemented with cycloheximide (CHX). EV, empty vector.

427 (c) Immunoprecipitation using anti-HA antibody in the strains *rqc2Δ vms1Δ* expressing Rqc2p
428 and Vms1p-V5 (control) or Rqc2p-HA and Vms1p-V5. Immunoblotting of HA and V5 were
429 used to identify Rqc2p and Vms1p, respectively.

430 (d) Polysome profile of the *rqc2Δ vms1Δ* strain expressing Rqc2p-HA and Vms1p-V5 treated
431 with CHX prior to fractionation using sucrose density centrifugation. The sedimentation of
432 ribosomal particles was inferred from the A_{254} profile (40S, 60S, 80S and polysomes) and the
433 distribution of the 60S subunit was confirmed by immunoblotting of the ribosomal subunit,
434 Rpl3p. Immunoblotting of HA and V5 was used to detect Rqc2p and Vms1p, respectively.

Figure 2



435 **Figure 2. Vms1 is required for resolving RQC substrates.**


436 (a) Fluorescence microscopy analysis of the indicated strains expressing the FLAG-GFP^{Rz}
437 construct under the GPD promoter and the mitochondrial marker, mtRFP.

438 (b) Flow cytometry quantifications of FLAG-GFP accumulation in the indicated strains.
439 Median GFP intensity values are plotted ($n=3$, mean \pm s.e.m. **** $P < 0.0001$, P -value was
440 calculated using unpaired Student's t-test).

441 (c) Immunoblot analysis of indicated strains expressing the FLAG-GFP^{Rz} construct.
442 Immunoblotting of Flag was used to detect the accumulation of the stalled construct. Pgk1p
443 was used as loading control.

444 (d) Fluorescence microscopy analysis of the indicated strains expressing the Fum1-FLAG-
445 GFP^{Rz} construct expressed from the *FUM1* endogenous promoter and the mitochondrial
446 marker, mtRFP.

Figure 3



447 **Figure 3. Vms1 is structurally homologous to tRNA hydrolases.**


448 (a) Domain structure of Vms1p. LRS, Leucine Rich Sequence; ZnF, Zinc Finger; MTD/eRFL,
449 Mitochondrial Targeting Domain/eRF1-like; AnkR, Ankryin Repeat; CC, Coil-Coil; VIM, VCP-
450 Interacting Motif. Residues 188-417 represent the MTD/eRFL boundaries.

451 (b) Structural alignment of Vms1p (left, 5WHG) and eRF1p (middle, 3JAHii, residues 144-
452 280). Dashed lines indicate connections made by residues that are not resolved in the Vms1p
453 crystal structure. The GGQ (red) loop of eRF1p is ordered in the ribosome-bound structure
454 shown here.

455 (c) Sequence alignment of Vms1p and eRF1p. White letters with gray, black, or red
456 background indicates similarity, identity, or GxxQ residues, respectively.


457 (d) Sequence alignment of Vms1p orthologs across the GxxQ region. Coloring as in (c).

458 (e,f) Serial dilutions of indicated strains were spotted on media containing glucose or glucose
459 supplemented with cycloheximide (CHX). EV, empty vector.



460 **Figure 4. Vms1p exhibits tRNA hydrolase activity towards RQC substrates.**

461 (a) Time courses of *S. cerevisiae* in vitro translation (SciVT) reactions prepared with a
462 truncated mRNA (lacking a stop codon). Extract genotypes are indicated above. Peptides

463 that have been CAT-tailed and released are denoted by: 

464 (b) Quantification of peptidyl-tRNA species in (a). Mean \pm s.e.m, $n=6$. **** $P < 0.0001$. P -value
465 was calculated using a 2-way ANOVA.


466 (c) Time courses of SciVT reactions prepared as in (a).

467 (d) Quantification of peptidyl-tRNA species in (c). Mean \pm s.e.m, $n=8$. **** $P < 0.0001$. P -value
468 was calculated using a 2-way ANOVA.

469 (e) SciVT reactions prepared as in (a) with a *vms1* Δ extract. At $t=15$, buffer (-) or pure
470 protein was added. Slopes indicate a titration series of decreasing protein concentrations
471 (see Methods). FL = Full Length Vms1; 1-417 = N-terminus through eRFL domain.

472 (f) SciVT reactions prepared as in (a) with a *vms1* Δ extract. At $t=15$, buffer, WT(1-417)
473 protein, or mutant(1-417) protein was added.

Extended Data Figure 1



474 **Extended Data Figure 1.**

475 (a) Serial dilutions of indicated strains were spotted on media containing glucose or glucose
476 supplemented with cycloheximide (CHX) and grown for 2 or 3 days, respectively.

477 (b) Serial dilutions of the indicated strains were spotted on medium containing glucose or
478 glycerol and grown for 2 or 3 days, respectively.


479 (c) Immunoprecipitations using anti-HA antibody in the *rqc1Δ vms1Δ* strain expressing
480 Rqc1p and Vms1p-V5 (control) or Rqc1p-HA and Vms1p-V5. Immunoblotting of HA and V5
481 were used to identify Rqc1p and Vms1p, respectively.

482 (d) Immunoprecipitations using anti-HA antibody in the *ltn1Δ vms1Δ* strain expressing Ltn1p
483 and Vms1p-V5 (control) or Ltn1p-HA and Vms1p-V5. Immunoblotting of HA and V5 were
484 used to identify Ltn1p and Vms1p, respectively.


485 (e) Polysome profiles of whole cell extracts from the *vms1Δ rqc2Δ* strain expressing Rqc2p-
486 HA and Vms1p-V5, Vms1p-V5, Rqc2p-HA or the Rqc2p CAT-tailing-defective mutant Rqc2p-
487 D98Y from top to bottom, respectively. Strains were treated with CHX prior to fractionation by
488 sucrose density centrifugation. Chromatographic analysis (A_{254}) was used to determine the
489 distribution of the 40S, 60S, 80S and polysome content of the 16 collected fractions.
490 Immunoblot analysis was performed only on fractions 3-11. The distribution of the 60S subunit
491 was confirmed by immunoblotting of the ribosomal subunit, Rpl3p. Immunoblotting of HA and
492 V5 was used to detect Rqc2p and Vms1p, respectively.

493 (f) Polysome profiles of whole cell extracts from the *vms1Δ rqc2Δ* strain expressing Rqc2p-HA
494 and Vms1p-V5 under the *GAL*-inducible promoter after galactose induction for 4, 8 and 16 hr
495 from top to bottom, respectively. Chromatographic analysis (A_{254}) was used to determine the
496 distribution of the 40S, 60S, 80S and polysome content of the 16 collected fractions. The
497 distribution of the 60S subunit was confirmed by immunoblotting of the ribosomal subunit,
498 Rpl3p. Immunoblotting of HA and V5 was used to detect Rqc2p and Vms1p, respectively.


a



b



c



499 **Extended Data Figure 2.**

500 (a) Gating strategy for analyzing FLAG-GFP positive cells. Panel shows gating parameters
501 for collection of total GFP intensity, excluding cellular debris in WT, *ski7Δ* and *ski7Δvms1Δ*.
502 SSC, Side Scatter light; FSC, Forward Scatter light; PE, phycoerythrin; FITC, Fluorescein
503 isothiocyanate. PE was plotted but not analyzed in this study.


504 (b) Immunoblot analysis of whole cell extracts from the indicated strains expressing the
505 FLAG-GFP^{Rz} construct (same as in Fig. 2). Immunoblotting of Flag (overexposed) was used
506 to detect the accumulation of aggregates in the stacking portion of the gel.

507 (c) qRT-PCR analysis of the indicated strains expressing the FLAG-GFP^{Rz} construct ($n=3$,
508 data are mean \pm s.e.m. $**P < 0.002$ and $*P < 0.01$, P -value was calculated using unpaired
509 Student's t-test).


a

Description	Chain	Z score	RMSD	Iali	%ID
Elongation factor I-alpha	3vmf-B	6.9	3.4	111	6
Eukaryotic peptide chain release factor 1	3e1y-C	6.8	4.1	109	4
Eukaryotic peptide chain release factor	1dt9-A	6.6	3.1	105	4
Peptide chain release factor 1	4af1-A	6.5	4.0	116	8
Dom34	2vgn-A	6.5	5.0	115	7
Pelota	3obw-A	6.4	3.9	103	13
Dom34	3izq-0	6.0	4.0	122	6
Elongation factor 1-alpha	3agj-B	6.0	4.1	121	7
Pelota	3oby-A	5.9	4.3	120	4
Ribonuclease E	2c0b-L	5.9	3.1	92	11


b




c



d



e



510 **Extended Data Figure 3.**

511 (a) Similar structures to the Vms1p MTD/eRFL returned from the Dali server²⁷. Z-score
512 indicates degree of structural similarity, with above 2 being a similar fold. lali, number of
513 aligned residues; %ID, percent identical residues.





514 (b) Serial dilutions of *ltn1Δ vms1Δ* cells with the indicated plasmids were spotted on synthetic
515 media supplemented with glucose or glycerol.

516 (c) Serial dilutions of indicated strains were spotted on glucose, glycerol and glucose
517 supplemented with cycloheximide (CHX) and grown for 2 or 3 days, respectively.

518 (d) Flow cytometry quantifications of FLAG-GFP accumulation in the indicated strains.
519 Median GFP intensity values ($n=4$, data are mean \pm s.e.m. ** $P < 0.004$, *** $P < 0.0002$, **** $P <$
520 0.0001 , P -value was calculated using unpaired Student's t-test).


521 (e) Immunoprecipitation using the anti-HA antibody in the *rqc2Δ vms1Δ* strain expressing
522 Rqc2p and Vms1p-V5 (control); Rqc2p-HA and Vms1p-V5; or Rqc2p-HA and Vms1p-V5
523 mutants. Immunoblotting of HA and V5 was used to identify Rqc2p and Vms1p, respectively.

Extended Data Figure 4



524 **Extended Data Figure 4.**

525 (a) Time courses of *S. cerevisiae* in vitro translation (SciVT) reactions prepared with a
526 truncated mRNA (lacking a stop codon). Extract genotypes are indicated above. Peptides

527 that have been CAT-tailed and released are denoted by: 

528 (b) SciVT reactions prepared as in (a) with WT, *rqc2Δ*, or *vms1Δ* extracts. At $t=15$, buffer
529 (-) or pure protein (4.2 μ M final) was added. FL = Full Length Vms1; 1-417 = N-terminus
530 through eRF1-like domain.

531 (c) SciVT reactions prepared as in (a) with a *vms1Δ* extract. At $t=15$, buffer, WT(1-417), or
532 mutant(1-417) protein was added (see Methods).

533 (d) Coomassie staining of purified Vms1 proteins used in SciVT rescue experiments. FL =
534 Full Length; 1-417 = N-terminus through eRF1-like domain.